Position in LYEL
as of Jun 30, 2026
· filed Aug 17, 2026
Position Value
$8,168,768
-$3,422,040 QoQ
Shares Held
581,407
+0.6% QoQ
Ownership
2.37%
of shares outstanding
% of Portfolio
2.01%
of 13F equity value
Holder Rank
#7
of 87 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Almitas Capital LLC holds $38,543,506 across 6 Biotechnology names. LYEL ranks #2 (21.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DSGN |
Design Therapeutics, Inc.
|
1,026,893 | $14,859,141 | |
| 2 | LYEL |
Lyell Immunopharma, Inc.
This page
|
581,407 | $8,168,768 | |
| 3 | ANTX |
AN2 Therapeutics, Inc.
|
1,469,129 | $7,110,584 | |
| 4 | ALXO |
Alx Oncology Holdings Inc
|
2,938,431 | $6,082,552 | |
| 5 | RLYB |
Rallybio Corp
|
120,682 | $1,930,912 | |
| 6 | CABA |
Cabaletta Bio, Inc.
|
125,900 | $391,549 |
All Filings in LYEL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8,168,768 | 581,407 | Shares | Sole | 2026-08-17 | |
| 2026-03-31 | $11,590,808 | 577,807 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $17,784,899 | 577,807 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $9,383,585 | 577,807 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $5,127,173 | 579,997 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $1,335,642 | 2,482,606 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $672,332 | 1,050,520 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||